all on track

Tisssue Therapies Update on EU Sales Launch

Biomedical company, Tissue Therapies Limited (ASX: TIS) has today confirmed that all milestones) are on track for the startof VitroGro(R) sales in early June 2012 in the UK and Europe.

Final validation data are as expected and confirm that the VitroGro(R) ECM manufacturing processes are reliable and compliantwith the necessary Good Manufacturing Process (GMP) standards.

Working with our partner Quintiles, advertising for and interviewing of potential UK and European sales staff has identified a pool of strong, experienced candidates from whom final selection and employment offers will be made.
Key, influential wound healing clinicians in the UK and Europe are keen to be involved in the initial clinical use of VitroGro(R) ECM and a number of these are providing their expert advice on a range of launch activities including sales training and reimbursement.


Logistics, multilingual customer support, order and payment processes are also in place with our partner Movianto.


The CEO, Dr Steven Mercer said, “The company remains confident about CE mark approval. We will also be rolling out an integrated communications program for the launch of VitroGro(R). This will include publications, scientific and clinical papers and presentations at selected conferences.”


“We believe we have a proven, unprecedented product for the definitive treatment of diabetic and venous ulcers. VitroGro(R) ECM offers for the first time ever, consistent healing as well as better price performance than any product previously available to treat these debilitating and sometimes fatal wounds” “We have the product to launch in the EU and $10 million in cash. This is an exciting time for Tissue Therapies.”